These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16472271)

  • 1. Cardiac amyloidosis--sustained clinical and free light chain response to low dose thalidomide and corticosteroids.
    Campbell P; Murdock C
    Intern Med J; 2006 Feb; 36(2):137-9. PubMed ID: 16472271
    [No Abstract]   [Full Text] [Related]  

  • 2. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis.
    Sanchorawala V; Finn KT; Fennessey S; Shelton A; Doros G; Zeldis JB; Seldin DC
    Blood; 2010 Sep; 116(11):1990-1. PubMed ID: 20847211
    [No Abstract]   [Full Text] [Related]  

  • 3. Coexistence of primary AL amyloidosis and POEMS syndrome: efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course.
    Adami F; Briani C; Binotto G; Altinier S; Tarantini G; Semenzato G
    Am J Hematol; 2010 Feb; 85(2):131-2. PubMed ID: 20029992
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.
    Palladini G; Russo P; Lavatelli F; Nuvolone M; Albertini R; Bosoni T; Perfetti V; Obici L; Perlini S; Moratti R; Merlini G
    Ann Hematol; 2009 Apr; 88(4):347-50. PubMed ID: 18779964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloidosis.
    Benjamin M; Gibbs S
    BMJ; 2011 Nov; 343():d6326. PubMed ID: 22088395
    [No Abstract]   [Full Text] [Related]  

  • 6. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
    Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
    J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New possibilities of the diagnosis and monitoring of the course of AL-amyloidosis].
    Rameev VV; Kozlovskaia LV; Kogarko IN; Kogarko BS
    Ter Arkh; 2010; 82(6):29-32. PubMed ID: 20731106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.
    Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Witzig TE; Fonseca R; Lust JA; Greipp PR; Kyle RA; Gertz MA
    Amyloid; 2003 Dec; 10(4):257-61. PubMed ID: 14986485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.
    Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO
    Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
    Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
    Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.
    Seldin DC; Choufani EB; Dember LM; Wiesman JF; Berk JL; Falk RH; O'Hara C; Fennessey S; Finn KT; Wright DG; Skinner M; Sanchorawala V
    Clin Lymphoma; 2003 Mar; 3(4):241-6. PubMed ID: 12672274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis.
    Morris KL; Tate JR; Gill D; Kennedy G; Wellwood J; Marlton P; Bird R; Mills AK; Mollee P
    Intern Med J; 2007 Jul; 37(7):456-63. PubMed ID: 17547724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).
    Palladini G; Perfetti V; Perlini S; Obici L; Lavatelli F; Caccialanza R; Invernizzi R; Comotti B; Merlini G
    Blood; 2005 Apr; 105(7):2949-51. PubMed ID: 15572585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
    Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
    Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemphigus vulgaris with involvement of the cervix treated using thalidomide therapy.
    Cunha PR; de Oliveira JR; Salles MJ; Jamora J; Bystryn JC
    Int J Dermatol; 2004 Sep; 43(9):682-4. PubMed ID: 15357753
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomide, Cyclophosphamide, and Dexamethasone.
    Kikukawa Y; Hata H; Ueda M; Yamashita T; Nasu S; Ide K; Ueno S; Ando Y; Mitsuya H; Okuno Y
    Intern Med; 2016; 55(18):2707-12. PubMed ID: 27629972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Mehta J
    N Engl J Med; 2008 Jan; 358(1):91; author reply 92-3. PubMed ID: 18175385
    [No Abstract]   [Full Text] [Related]  

  • 19. Prurigo nodularis of Hyde treated with low-dose thalidomide.
    Orlando A; Renna S; Cottone M
    Eur Rev Med Pharmacol Sci; 2009; 13(2):141-5. PubMed ID: 19499850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
    Sviggum HP; Davis MD; Rajkumar SV; Dispenzieri A
    Arch Dermatol; 2006 Oct; 142(10):1298-302. PubMed ID: 17043184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.